Successful fresh formulation CD19 CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. A Case Report - PubMed
3 days ago
- #GAD65 antibody
- #CAR-T cell therapy
- #autoimmune cerebellar ataxia
- CD19 CAR-T cell therapy was successfully used to treat GAD65 antibody-mediated cerebellar ataxia in a 33-year-old male.
- The patient showed a 95% reduction in GAD65 serum titers by day +90 and significant clinical improvement in ataxia by day +30.
- No disease progression was observed at day +270, with toxicity limited to cytokine release syndrome grade 1.
- The case supports further study of CD19 CAR-T cell therapy for GAD65 neurological disorders due to its efficacy and limited toxicity.